Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 22 August 2024)
| Date | 22 August 2024 |
|---|---|
| Court | CFI |
| Division | Munich (DE) Central Division - Section |
| Type of action | Application RoP262.1 (b) |
| Case number(s) | UPC_CFI_75/2023 |
| Registry reference | App_588681/2023 · ORD_591107/2023 · UPC_CFI_75/2023 |
| Parties | Astellas v. Helios, Riken, Osaka |
Official decision (PDF) · UPC registry entry
Case timeline
- 21 September 2023 : Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 21 September 2023) ORD_552745/2023 · UPC_CFI_75/2023
- 11 October 2023 : Astellas Institute for Regenerative Medicine v Healios K.K (CFI, UPC_CFI_75/2023, 11 October 2023) ORD_579543/2023 · UPC_CFI_75/2023
- 28 December 2023 : Mathys & Squire v Astellas (CFI, 28 December 2023) App_588681/2023 · UPC_CFI_75/2023
- 18 March 2024 : Astellas Institute for Regenerative Medicine v Healios K.K. (CFI, 18 March 2024) ACT_464985/2023 · ORD_598255/2023 · UPC_CFI_75/2023
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
By order of 22 August 2024 (UPC_CFI_75/2023, ACT_464985/2023, ORD_591107/2023), the judge-rapporteur of the Munich Central Division (A. Kupecz) granted the firm Mathys & Squire access to the pleadings and evidence in the revocation action on EP 3 056 563 brought by Astellas Institute for Regenerative Medicine against Healios, Riken and Osaka University, after redaction of personal data and of the confidential passages identified by Astellas. The order confirms that once proceedings have ended in settlement, a general interest is enough to obtain access.
Question
May a third party showing only a general interest obtain access to the pleadings and evidence of proceedings ended by settlement, and may the claimant obtain redaction of sensitive information?
Decision
The judge had awaited the Court of Appeal decision of 10 April 2024 on public access before ruling. As the proceedings ended on 23 July 2024 on the parties’ joint application, the applicant’s general interest suffices and Astellas’s objection that there was no direct interest fails: once the case has ended in settlement, the balance of interests will normally favour access. No abuse, public order ground or third-party interest stands in the way. Astellas’s interest is protected by redaction, justified by the commercial risk and by the fact that the applicant may act for competitors, of information on its product timeline in its reply of 29 November 2023 and in the rejoinder of 29 December 2023 (Rule 262.2 RoP). Personal data is redacted under Regulation (EU) 2016/679. Leave to appeal is granted and access is deferred for 16 days after service.
Key points for practice
- Practical point: settlement does not shield the file from the public, a party wishing to protect information must seek precise, reasoned redactions.
Provisions applied
- Agreement on a Unified Patent Court
- Arts. 10, 45 and 73(2)(b)(ii)
- Rules of Procedure
- Rules 220.2, 224.1(b) and 262
- Regulation (EU) 2016/679
- protection of personal data
- Case law cited
- Ocado Innovation v Autostore, Court of Appeal, 10 April 2024, Ocado Innovation v Autostore, Nordic-Baltic Regional Division, 17 October 2023, The Hague Local Division, 29 July 2024 (UPC_CFI_131/2024)
Related decisions
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Decisions in the same proceedings
Going further
Lexicon: Written procedure (UPC), Confidentiality club.
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Parties
- claimantAstellas2 decisions in the corpusFollow this party
- defendantHeliosFollow this party
- defendantRiken7 decisions in the corpusFollow this party
- defendantOsakaFollow this party
Decisions in the same proceedings and documented appeals
- 21 September 2023 Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 21 September 2023) Revocation Action · UPC_CFI_75/2023
La demande d'accès d'un tiers au mémoire introductif et à la lettre de signification est rejetée : l'éducation et la formation ne sont pas un motif légitime, et la lettre n'est ni une écriture ni une pièce.
- 11 October 2023 Astellas Institute for Regenerative Medicine v Healios K.K (CFI, UPC_CFI_75/2023, 11 October 2023) Revocation Action · UPC_CFI_75/2023
Le mémoire en défense à l'action en nullité est réputé signifié le 29 septembre 2023, la notification générée par le CMS valant signification au sens de la règle 278.1.
- 28 December 2023 Mathys & Squire v Astellas (CFI, 28 December 2023) Application RoP262.1 (b) · UPC_CFI_75/2023
La demande d'accès de Mathys & Squire est mise en attente jusqu'à la décision de la cour d'appel sur la règle 262.1 b), à produire dans les trois semaines.
- 18 March 2024 Astellas Institute for Regenerative Medicine v Healios K.K. (CFI, 18 March 2024) Revocation Action · UPC_CFI_75/2023
Le document D18 est admis sous réserve d'une réponse de la défenderesse avant le 11 avril 2024, la valeur du litige est fixée à 4 000 000 euros et l'audience confirmée au 25 juin 2024.
- 22 August 2024 Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 22 August 2024) Application RoP262.1 (b) · UPC_CFI_75/2023
What the record states
- Nature of the act
- Application RoP262.1 (b)
- Outcome (Dhenne Avocats summary)
- Mathys & Squire obtient l'accès aux écritures et pièces de l'action en nullité close par transaction, après occultation des données personnelles et des informations confidentielles d'Astellas. L'appel est autorisé.
- Appeal
- No appeal documented in the corpus, this does not mean that no appeal was lodged.
- Instance
- First-instance decision, whether it has become final is not recorded.
Patents mentioned
EP 3 056 563mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- Ocado Innovation v Autostore (CoA, 10 April 2024) cited in this record
- Astellas Institute for Regenerative Medicine v Healios K.K. (CFI, 18 March 2024) cited in this record
- Mathys & Squire v Astellas (CFI, 28 December 2023) cited in this record
- OCADO INNOVATION v AUTOSTORE (CFI, 17 October 2023) cited in this record
- Astellas Institute for Regenerative Medicine v Healios K.K (CFI, UPC_CFI_75/2023, 11 October 2023) cited in this record
- Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 21 September 2023) cited in this record
- Astellas Institute for Regenerative Medicine v Healios K.K. (CFI, ORD_464985/2023, 16 June 2023) cited in this record
- Dolby International v Optoma Deutschland (CFI, 28 July 2026) cites this decision
- Vereenigde Octrooibureaux v Dolby International (CFI, 24 July 2026) cites this decision
- Franz Kaldewei v Bette (CFI, 23 July 2026) cites this decision
- Dolby International v Beko Germany (CFI, 9 April 2025) cites this decision
- Bhagat Textile Engineers v Oerlikon Textile (CFI, 20 February 2025) cites this decision
- Mathys & Squire v Astellas Institute for Regenerative Medicine (CFI, 4 November 2024) cites this decision
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 3 056 563Method of producing retinal pigment epithelial cell recorded proprietor: Healios KK, RIKEN et University of Osaka NUC | Mentioned in the analysis (role not qualified) Also mentioned in 7 other decision(s): Mathys & Squire v Astellas Institute for Regenerative Medicine (CFI, 4 · Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 23 Ju · Astellas Institute for Regenerative Medicine v Healios K.K. (CFI, 18 M · Mathys & Squire v Astellas (CFI, 28 December 2023) · Astellas Institute for Regenerative Medicine v Healios K.K (CFI, UPC_C · Astellas Institute for Regenerative Medicine v Healios K.K (CFI, 21 Se · Astellas Institute for Regenerative Medicine v Healios K.K. (CFI, ORD_ | not recorded | not recorded | not recorded | Espacenet · European Patent Register existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically) mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.